Safety and efficacy of delandistrogene moxeparvovec versus placebo in Duchenne muscular dystrophy (EMBARK): Pivotal Phase 3 primary results

JR Mendell,*,1,2,† F Muntoni,3 CM McDonald,4 EM Mercuri,5 E Ciafaloni,6 H Komaki,7 C Leon-Astudillo,8 A Nascimento,9 C Proud,10 U Schara-Schmidt,11 A Veerapandiyan,12 CM Zaidman,13 M Guridi,14 AP Murphy,15 C Reid,15 C Wandel,14 DR Asher,16 E Darton,16 S Mason,16 RA Potter,16 T Singh,16 W Zhang,16 P Fontoura,14 JS Elkins,16 LR Rodino-Klapac16 on behalf of the EMBARK Study Group

¹Center for Gene Therapy, Nationwide Children's Hospital, Columbus, OH, USA; ²The Ohio State University, Columbus, OH, USA; ³The Dubowitz Neuromuscular Centre, Reat Ormond Street Institute of Child Health and Institute of Neurology, University College London, and Great Ormond Street Hospital Trust, London, UK; ⁴UC Davis Health, Sacramento, CA, USA; ⁵Pediatric Neurology Institute, Catholic University and Nemo Pediatrico, Fondazione Policlinico Gemelli IRCCS, Rome, Italy; ⁶University of Rochester Medical Center, Rochester, NY, USA; ¬Translational Medical Center, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan; ⁶Department of Pediatrics, University of Florida, Gainesville, FL, USA; ⁶Neuromuscular Unit, Neuropaediatrics Department, Hospital Sant Joan de Déu, CIBERER – ISC III, Barcelona, Spain; ⁶Children's Hospital of the King's Daughters, Norfolk, VA, USA; ¹¹Department of Pediatric Neurology, Center for Neuromuscular Disorders in Children and Adolescents, University of Duisburg-Essen, Essen, University of Pediatrics, Division of Neurology, University of Arkansas for Medical Sciences, Arkansas Children's Hospital, Little Rock, AR, USA; ¹³Department of Neurology, Washington University in St Louis, MO, USA; ¹⁴F. Hoffmann-La Roche Ltd, Welwyn Garden City, UK; ¹⁶Sarepta Therapeutics, Inc., Cambridge, MA, USA

*Presenting on behalf of the author group (email address: medinfo@sarepta.com); †At the time of study.

What does this study mean for the DMD community?

- The totality of evidence indicates that delandistrogene moxeparvovec produces potential beneficial disease trajectory modification versus placebo with a manageable safety profile.
 - EMBARK Part 2 will provide 2-year data for patients treated in Part 1, allowing progression to be monitored and adding to longer-term data.

Conclusions

- Safety findings demonstrate the manageable benefit—risk profile of delandistrogene moxeparvovec with no new safety signals identified, and no deaths, study discontinuations or clinically relevant complement-mediated AEs.
- Delandistrogene moxeparvovec did not reach statistical significance compared with placebo in the primary endpoint of NSAA at 52 weeks.
- Between-group differences favoring delandistrogene moxeparvovec on secondary functional endpoints indicate the potential for long-term disease modification of DMD.
- The GST supported the totality of evidence of the beneficial effect of delandistrogene moxeparvovec on motor function.
 A post hoc analysis of TTR showed fewer delandistrogene moxeparvovec-treated patients progressing to a TTR >5 seconds, a prognostic marker for accelerated disease progression and earlier loss of ambulation.


OBJECTIVE

• We present an overview of the 1-year safety and functional outcomes from Part 1 of EMBARK.

BACKGROUND

- Delandistrogene moxeparvovec is a rAAV vector-based gene therapy, designed to compensate for the absence of functional dystrophin in DMD by delivering a transgene encoding delandistrogene moxeparvovec micro-dystrophin, an engineered protein that retains key functional domains of the wild-type protein.^{1–3}
- As of February 2024, delandistrogene moxeparvovec is approved in the USA, UAE, Qatar and Kuwait for the treatment of ambulatory pediatric patients aged 4 through 5 years with DMD with a confirmed mutation in the *DMD* gene. Delandistrogene moxeparvovec is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the *DMD* gene.^{4–7}
- EMBARK (NCT05096221)⁸ is a Phase 3, two-part, multinational, randomized, double-blind, placebo-controlled study assessing the safety and efficacy of delandistrogene moxeparvovec in patients with DMD aged ≥4 to <8 years.

Figure 1. Overview of delandistrogene moxeparvovec




*ITRs are required for genome replication and packaging. †PolyA signals the end of the transgene to the cellular machinery that transcribes (i.e. copies) it.

Delandistrogene Placebo

STUDY DESIGN AND ENDPOINTS⁸

Figure 2. EMBARK study design schematic



Stratification based on age at randomization (≥4 to <6 or ≥6 to <8 years) and NSAA score at screening (≤22 vs. >22).

Key inclusion criteria

- Ambulatory males aged ≥4 to <8 years at randomization.
- Confirmed DMD diagnosis (*DMD* mutation fully contained between exons 18 to 79 [inclusive]).
- Ability to cooperate with motor assessment testing.
 NSAA score >16 and <29 points at screening.
- TTR <5 seconds at screening.

Safety endpoints

 On a stable daily dose of oral corticosteroids for ≥12 weeks before screening.

Clinically significant changes in laboratory assessments.

GST for totality of evidence analysis on a composite of

The primary endpoint and secondary endpoints were

tested using a statistical hierarchy to control the overall

Type I error at a 2-sided level of 0.05[†]

rAAVrh74 total binding antibody titers <1:400 (i.e. not elevated).

TEAEs, SAEs and AEs of special interest.

Additional pre-specified efficacy analyses

endpoints through permutations.^{10,11}

Endpoints

Primary endpoint

Change from baseline to Week 52 in NSAA total score.
 Key secondary functional endpoints

Change from baseline to Week 52 in:

- TTR - 10M\WR

Other secondary functional endpoints

- Change from baseline to Week 52 in:

 SV95C as measured by a wearable device
- (Syde®)
- 100MWRTime to ascend 4 steps.

*Only a subset of patients will receive a muscle biopsy for expression assessments, based on site experience and feasibility. †Additional endpoints were included in the sequential testing, that are not reported in this presentation.



RESULTS

Demographics and clinical characteristics

 Patient demographics and baseline clinical characteristics were balanced between delandistrogene moxeparvovec and placebo groups.

Characteristic	moxeparvovec (n=63)	(n=62)	(N=125)	
Mean age, years (SD)	5.98 (1.06)	6.08 (1.05)	6.03 (1.05)	
4-5 years, n (%)	30 (47.6)	29 (46.8)	59 (47.2)	
6-7 years, n (%)	33 (52.4)	33 (53.2)	66 (52.8)	
Mean dosing weight, kg (SD)	21.29 (4.62)	22.37 (6.42)	21.83 (5.59)	
Mean time since corticosteroid treatment started, years (SD)	1.07 (0.92)	0.97 (0.83)	1.02 (0.88)	
Primary and key secondary functional endpoints				
Mean NSAA total score, points				

Mean NSAA total score, points (SD)	23.10 (3.75)	22.82 (3.78)	22.96 (3.75)
Mean TTR, seconds (SD)	3.52 (0.81)	3.60 (0.68)	3.56 (0.75)
Mean 10MWR, seconds (SD)	4.82 (0.79)	4.92 (0.73)	4.87 (0.76)
Mean SV95C, meters/second (SD)*	1.82 (0.30)	1.77 (0.29)	1.79 (0.30)
Mean 100MWR, seconds (SD) [†]	60.67 (15.55)	63.01 (17.01)	61.80 (16.25)
Mean time to ascend 4 steps, seconds (SD) [‡]	3.17 (1.01)	3.37 (1.09)	3.27 (1.05)

*SV95C: Delandistrogene moxeparvovec n= 61, placebo n=62, total N=123. †100MWR: Delandistrogene moxeparvovec n=63, placebo n=59, total N=122. ‡Time to ascend 4 steps: Delandistrogene moxeparvovec n=63, placebo n=61, total N=124.

Safety overview


	Delandistrogene moxeparvovec (n=63)	Placebo (n=62)
Patients with any TEAE, n (%)	62 (98.4)	57 (91.9)
TEAEs, n	664	502
Patients with any TR-TEAE, n (%)	48 (76.2)	17 (27.4)
TR-TEAEs, n	235	43
Patients with any TR-SAE, n (%)	7 (11.1)	0
TR-SAEs, n	10	0
Patients with an AE leading to study discontinuation, n (%)	0	0
Deaths, n (%)	0	0

- The safety profile of delandistrogene moxeparvovec in EMBARK was consistent with experience from early phase studies.
- AEs were medically manageable with appropriate monitoring and treatment.
- There were no clinically relevant complement activation AEs, no deaths and no study discontinuations.

Primary endpoint

Figure 3. Change from baseline to Week 52 in NSAA total score

Vector




*The widths of CIs have not been adjusted for multiplicity and cannot be used to infer definitive treatment effects. †One patient in the placebo group had missing data at Week 52; the patient's functional tests were marked as invalid by the clinical evaluator due to back pain from compression fractures.

Summary of functional endpoints

Figure 4. Functional endpoints at Week 52 in the overall population

Favors delandistrogene



-2 -1 0 1 2 3 4 5


Standardized statistics for the primary analysis (95% CI)

*Since the primary endpoint did not meet statistical significance, all *P*-values resulting from subsequent hierarchical testing are presented with no multiplicity adjustment (nominal). The widths of CIs have not been adjusted for multiplicity and cannot be used to infer definitive treatment effects

LSMs (of change from baseline) and CIs were standardized by dividing by the SE. Negative values for timed function tests (TTR, 10MWR, 100MWR and time to ascend 4 steps) show an improvement in the time taken to achieve these endpoints. LSM differences are on original scale (without SE adjustment). Signs of timed function tests were reversed in the forest plot to align favorable directions among endpoints. Numerical results of LSM difference kept the original signs.

Key secondary functional endpoints

Figure 5. Change from baseline to Week 52 in a) TTR and b) 10MWR



Negative values indicate an improvement in the time taken to achieve these endpoints.
 The separation between groups was clinically relevant for both TTR and 10MWR.

*Since the primary endpoint did not meet statistical significance, all *P*-values resulting from subsequent hierarchical testing of endpoints are presented with no multiplicity adjustment (nominal). The widths of CIs have not been adjusted for multiplicity and cannot be used to infer definitive treatment effects. †One patient in the placebo group had missing data at Week 52; the patient's functional tests were marked as invalid by the clinical evaluator due to back pain from compression fractures.

Pre-specified GST

- A pre-specified GST was performed as an additional exploratory analysis to assess overall treatment effects.
- The test was on a composite of functional endpoints (Primary endpoint: NSAA total score; Key secondary functional endpoints: TTR, 10MWR; Other secondary functional endpoints: SV95C, 100MWR, ascend 4 steps).
- The GST supported the totality of evidence of treatment benefit with delandistrogene moxeparvovec compared with placebo (*P*=0.0044).

Post hoc analyses on TTR

- All patients had a TTR <5 seconds at screening.
 With delandistrogene moxeparvovec treatment,
- With delandistrogene moxeparvovec treatment, fewer patients progressed to a TTR >5 seconds compared with placebo.

A TTR >5 seconds is a threshold of prognostic
significance for loss of ambulation. 12,13

Patients with TTR >5 seconds
at Week 52

Delandistrogene
moxeparvovec (n=63)

Placebo (n=61)

Placebo (n=61)

91%
(P=0.0135)

NSAA .

The heterogeneity of DMD disease progression is a challenge when designing trials of short duration in this study population and age range (4–7-year-olds). 44,15 – Motor function may still be improving, maintaining or starting to decline.

 A 1-point difference in the NSAA indicates different ranges of function, from inability to do a task, to using compensation, or performing with no compensation.¹⁴ In younger patients, neurodevelopmental maturation might also affect these achievements.¹⁶

.6

TFTs such as TTR and 10MWR may be more sensitive measures of functional change in this age range and study duration.¹⁴

Acknowledgments and disclosures The authors would like to thank the patients and their families for their particil Therapeutics, Inc., Cambridge, MA, USA and funded by Sarenta Therapeutic

The authors would like to thank the patients and their families for their participation in EMBARK and the investigators and trial staff involved in EMBARK. This study was sponsored by Sarepta Therapeutics, Inc., Cambridge, MA, USA and funded by Sarepta Therapeutics, Inc., Cambridge, MA, USA and F. Hoffmann-La Roche Ltd, Basel, Switzerland. Medical writing and editorial support were provided by Emily Turner, BSc, of Nucleus Global, in accordance with Good Publication Practice (GPP) 2022 guidelines (https://www.ismpp.org/gpp-2022) and were funded by Sarepta Therapeutics, Inc., Cambridge, MA, USA and F. Hoffmann-La Roche Ltd, Basel, Switzerland. JRM received study funding from Sarepta Therapeutics while at Nationwide Children's Hospital at the time of the study and is currently an employee of Sarepta Therapeutics. JRM is a co-inventor of AAVrh74.MHCKT.micro-dys technology. FM has received honoraria and grants from Sarepta Therapeutics clinical trials. He reports participation in advisory boards for Novartis, F. Hoffmann-La Roche Ltd, Edgewise, Dyne Therapeutics, PTC Therapeutics, and Italfarmaco. CMM reports grants from Capricor, Catabasis, Edgewise, Epirium Blo, Italfarmaco, Pfizer, PTC Therapeutics, Santhera Pharmaceuticals, Sarepta Therapeutics: and has a consultancy/advisory role with Biomarin, Capricor, Catalyst, Edgewise, Italfarmaco, PTC Therapeutics, F. Hoffmann-La Roche Ltd, Santhera Pharmaceuticals, and Sarepta Therapeutics. Has received fees from AveXis, Biogen, and F. Hoffmann-La Roche Ltd, Santhera Pharmaceuticals, and Sarepta Therapeutics. The participating in advisory boards, and grants as an investigator in Sarepta Therapeutics consultancy/advisory role with Moral Pharmaceutical Co., Liquid Pharmaceutical C

Abbreviations 10MWR, 10-meter Walk/Run; 100MWR, 100-meter Walk/Run;

AAVrh74, adeno-associated virus rhesus isolate serotype 74; AE, adverse event; CI, confidence interval; DMD, Duchenne muscular dystrophy; GST, global statistical test; ITR, inverted terminal repeat; IV, intravenous; LSM, least-squares mean; NSAA, North Star Ambulatory Assessment; OH, hydroxide; polyA, polyadenylation; rAAV, recombinant adeno-associated virus; rAAVrh74, recombinant adeno-associated virus rhesus isolate serotype 74; SAE, serious adverse event; SD, standard deviation; SE, standard error; ssDNA, single-stranded DNA; SV95C, stride velocity 95th centile; TEAE, treatment-emergent adverse event; TR-SAE, treatment-related serious adverse event; TR-TEAE, treatment-related treatment-emergent adverse event; TR-TEAE, treatment-related treatment-emergent adverse event; TTR, Time to Rise; UAE, United Arab Emirates.

References

Asher DR, et al. Expert Opin Biol Ther. 2020; 20:263–7. 274;
 Zheng C and Baum BJ. Methods Mol Biol. 2008; 8. 434:205–219;
 Mendell JR, et al. JAMA Neurol. 2020; 77:1122–1131; 9.

US Food and Drug Administration. ELEVIDYS™

TFTs

https://www.fda.gov/media/169679/download. Published 2023 (Accessed February 2024);
5. UAE Ministry of Health & Prevention. https://mohap.gov.ae/en/services/registered-medical-product-directory. Accessed February 2024;
6. Qatar Ministry of Public Health Update, 27 September 2023. Roche data on file;

Highlights of prescribing information.

 Kuwait Ministry of Health Update, 19 February 2024. Roche data on file;
 ClinicalTrials.gov. NCT05096221 (Accessed February 2024);
 Chandler RJ and Venditti CP. *Transl Sci Rare Dis.* 2016; 1:73–89;
 Wei LJ and Lachin JM. *J Am Stat Assoc.* 1984; 79:653–661;
 Li D. et al. JAMA Netw Open, 2020; 3:e1921306;

Wei LJ and Lachin JM. J Am Stat Assoc. 1984; 79:653–661;
 Li D, et al. JAMA Netw Open. 2020; 3:e1921306;
 McDonald CM, et al. Lancet. 2018; 391:451–461;
 Zambon AA, et al. Dev Med Child Neurol. 2022; 64:979–988;
 Muntoni F, et al. PloS One. 2019; 14:e0221097;
 Goemans N, et al. PloS One. 2020; 15:e0232870;
 Mercuri E, et al. PLoS One. 2016; 11:e0160195.



mobile device please scan using your QR reader application. NB: There may be associated costs for downloading data. These costs may be high if you are using your smartphone abroad. Please check your mobile data tariff or contact your service provider for more details.

To access the full poster on your

Safety and efficacy of delandistrogene moxeparvovec versus placebo in Duchenne muscular dystrophy (EMBARK): Pivotal Phase 3 primary results

JR Mendell,*,1,2,† F Muntoni,3 CM McDonald,4 EM Mercuri,5 E Ciafaloni,6 H Komaki,7 C Leon-Astudillo,8 A Nascimento,9 C Proud,10 U Schara-Schmidt,11 A Veerapandiyan,12 CM Zaidman,13 M Guridi,14 AP Murphy,15 C Reid,15 C Wandel,14 DR Asher,16 E Darton,16 S Mason,16 RA Potter,16 T Singh,16 W Zhang,16 P Fontoura,14 JS Elkins,16 LR Rodino-Klapac16 on behalf of the EMBARK Study Group


¹Center for Gene Therapy, Nationwide Children's Hospital, Columbus, OH, USA; ²The Ohio State University, Columbus, OH, USA; ³The Dubowitz Neuromuscular Centre, NIHR Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street Institute of Child Health and Institute of Neurology, University College London, and Great Ormond Street Hospital Trust, London, UK; ⁴UC Davis Health, Sacramento, CA, USA; ⁵Pediatric Neurology Institute, Catholic University and Nemo Pediatrico, Fondazione Policlinico Gemelli IRCCS, Rome, Italy; ⁶University of Rochester Medical Center, Rochester, NY, USA; ¹Translational Medical Center, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan; ⁶Department of Pediatrics, University of Florida, Gainesville, FL, USA; ⁶Neuromuscular Unit, Neuropaediatrics Department, Hospital Sant Joan de Déu, CIBERER – ISC III, Barcelona, Spain; ¹¹Children's Hospital of the King's Daughters, Norfolk, VA, USA; ¹¹Department of Pediatric Neurology, Center for Neuromuscular Disorders in Children and Adolescents, University of Duisburg-Essen, Essen, University of Arkansas for Medical Sciences, Arkansas Children's Hospital, Little Rock, AR, USA; ¹³Department of Neurology, Washington University in St Louis, St Louis, MO, USA; ¹⁴F. Hoffmann-La Roche Ltd, Basel, Switzerland; ¹⁵Roche Products Ltd, Welwyn Garden City, UK; ¹⁶Sarepta Therapeutics, Inc., Cambridge, MA, USA

*Presenting on behalf of the author group (email address: medinfo@sarepta.com); †At the time of study.

SUPPLEMENTARY INFORMATION

Other secondary functional endpoint:

Figure 1. Change from baseline to Week 52 in SV95C



- SV95C is a digital objective endpoint of ambulatory performance in patients' normal daily environment
- Patients in EMBARK wore the device on each ankle for 3 weeks prior to the clinic visits
- The change from baseline met the published MCID by the EMA¹
- EMBARK is the first randomized, placebo-controlled trial in DMD that showed clinical relevance to a therapy based on SV95C from a wearable device


*Since the primary endpoint did not meet statistical significance, all *P*-values resulting from subsequent hierarchical testing of endpoints are presented with no multiplicity adjustment (nominal). The widths of CIs have not been adjusted for multiplicity and cannot be used to infer definitive treatment effects. †A small number of patients did not have sufficient recorded hours at Week 52 for analysis.

→Placebo (n=61)^T

Other secondary functional endpoint:

Figure 2. Change from baseline to Week 52 in 100MWR

■ Delandistrogene moxeparvovec (n=57)




Negative values indicate an improvement in the time taken to achieve this endpoint

*Since the primary endpoint did not meet statistical significance, all *P*-values resulting from subsequent hierarchical testing of endpoints are presented with no multiplicity adjustment (nominal). The widths of CIs have not been adjusted for multiplicity and cannot be used to infer definitive treatment effects. †A small number of tests at either baseline or Week 52 were marked as invalid by the clinical investigator; the most common reason was due to behavior.

Other secondary functional endpoint:

Figure 3. Change from baseline to Week 52 in time to ascend 4 steps




Between-group difference LSM (SE):

- Negative values indicate an improvement in the time taken to achieve this endpoint
- The separation between groups was clinically relevant

*Since the primary endpoint did not meet statistical significance, all *P*-values resulting from subsequent hierarchical testing of endpoints are presented with no multiplicity adjustment (nominal). The widths of CIs have not been adjusted for multiplicity and cannot be used to infer definitive treatment effects. †A small number of tests at either baseline or Week 52 were marked as invalid by the clinical investigator; the most common reason was due to behavior.

Study group



Acknowledgments and disclosures

The authors would like to thank the patients and their families for their participation in EMBARK and the investigators and trial staff involved in EMBARK. This study was sponsored by Sarepta Therapeutics, Inc., Cambridge, MA, USA and F. Hoffmann-La Roche Ltd, Basel, Switzerland. Medical writing and editorial support were provided by Emily Turner, BSc, of Nucleus Global, in accordance with Good Publication Practice (GPP) 2022 guidelines (https://www.ismpp.org/gpp-2022) and were funded by Sarepta Therapeutics, Inc., Cambridge, MA, USA and F. Hoffmann-La Roche Ltd, Basel, Switzerland.

JRM received study funding from Sarepta Therapeutics while at Nationwide Children's Hospital at the time of the study and is currently an employee of Sarepta Therapeutics. JRM is a co-inventor of AAVrh74.MHCK7.micro-dys technology. FM has received study funding from Sarepta Therapeutics clinical trials. He reports participation in advisory boards for Novartis, F. Hoffmann-La Roche Ltd, Edgewise, Dyne Therapeutics, and Islaffarmaco, CMM reports grants from Capricor, Catalyst, Edgewise, Epirium Bio, Italfarmaco, PTC Therapeutics, Santhera Pharmaceuticals, Sarepta Therapeutics, and Sarepta Therapeutics, Fizer, PTC Therapeutics, EMM has received from AveXis, Biogen, and F. Hoffmann-La Roche Ltd, EC has received for sarepta Therapeutics, PTC. Therapeutics, Emperated Therapeutics, Eligible and advisory boards, and grants an investigator in Sarepta Therapeutics of inical trials. HK has received from Sarepta Therapeutics, PTC. Therapeutics, PTC. Therapeutics, PTC. Therapeutics, Chugai Pharmaceutical Co., Nippon Shinyaku Co., Nippon Shinyaku Co., Ltd, and Kaneka Corporation. HK has received from Sarepta Therapeutics, PTC. Therapeutics, Chugai Pharmaceutical Co., Nippon Shinyaku Co., Ltd, and Kaneka Corporation. HK has received from Sarepta Therapeutics, PTC. Therapeutics,

Abbreviations
100MWR, 100-meter Walk/Run;
CI, confidence interval; EMA,
European Medicines Agency;
LSM, least-squares mean;
MCID, minimal clinically
important difference; SE,
standard error; SV95C, stride
velocity 95th centile.

References 1 FMA Qualification

1. EMA. Qualification opinion on stride velocity 95th centile as a secondary endpoint in Duchenne Muscular Dystrophy measured by a valid and suitable wearable device. https://www.ema.europa.eu/en/documents/scientific-guideline/qualification-opinion-stride-velocity-95th-centile-secondary-endpoint-duchenne-muscular-dystrophy_en.pdf. Accessed February 2024.